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Abstract 
Background: A recent large-scale mega-genome-wide association study (GWAS) identified, for the 
first time, genetic variants at 12 loci significantly associated with attention-deficit/hyperactivity 
disorder (ADHD). In this study we use a powerful polygenic approach, with polygenic scores derived 
from the GWAS, to investigate the aetiological overlap between ADHD and frequently co-occurring 
traits and disorders. 
Methods: Polygenic risk scores for ADHD derived from the mega-GWAS (20,183 cases, 35,191 
controls) were computed in a large-scale adult population sample (N=135,726) recruited by the UK 
Biobank. Regression analyses were conducted to investigate whether polygenic risk for ADHD is 
associated with related traits and disorders in this population sample. The effects of sex were 
investigated via inclusion of an interaction term in the models.  
Results: Polygenic risk for ADHD significantly and positively predicted body mass index 
(R
2
=0.45%;P=5x10
-129
), neuroticism (R
2
=0.09%;P=2x10
-24
), depression (R
2
=0.11%;P=2x10
-13
), anxiety 
(R
2
=0.06%;P=3x10
-4
), risk-taking (0.12%;P=9x10
-25
), alcohol intake (R
2
=0.09%;P=8x10
-29
), smoking 
(R
2
=0.33%;P=4x10
-21
), alcohol dependency (R
2
=0.21%;P=5x10
-6
), and negatively predicted verbal-
numerical reasoning (R
2
=0.38%;P=5x10
-36
). Polygenic risk scores did not significantly predict 
schizophrenia or bipolar disorder, although this may be due to the small number of diagnostic cases. 
We found no interaction effects between polygenic risk for ADHD and sex on any phenotypes.   
Conclusions: Our findings suggest that common genetic variation underlying risk for clinically 
diagnosed ADHD also contributes to higher body mass index, neuroticism, anxiety and depressive 
disorders, alcohol and nicotine use, risk-taking and lower general cognitive ability in the general 
population. These findings suggest that the co-occurrence of several traits with ADHD is partly 
explained by the same common genetic variants. 
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Text 
Introduction 
A recent mega genome-wide association study (GWAS) was the first to identify 12 loci significantly 
associated with attention-deficit/hyperactivity disorder (ADHD) (1). The statistical power of this 
GWAS allows the investigation of aspects of the genetic aetiology of ADHD and its co-occurring 
features through polygenic approaches. Typically in polygenic risk analyses, composite scores, 
known as polygenic risk scores (PRS), are created for individuals based on the sum of their risk alleles 
across the genome, weighted by GWAS-derived effect sizes. These PRS optimise the genetic signal 
underlying complex traits and disorders and have been widely used to investigate shared genetic 
aetiology between phenotypes (2,3,4).  
 
Previous genome-wide association and candidate studies failed to identify rare and common genetic 
variants underlying ADHD that explain more than a small fraction of its heritability (5,6,7), despite 
the high heritability of ADHD estimated at 0.76 from twin studies (8) and estimated at 0.22-0.32 
based on single-nucleotide polymorphisms (SNPs) (1,9). The difficulty in identifying genetic variants 
has likely been due to low statistical power and the polygenic nature of ADHD, i.e. that risk is a 
consequence of many small genetic effects. This has been supported by recent polygenic studies 
that show that significant associations emerge when a high number of genetic variants are 
considered ‘en masse’ (1,10).  
 
ADHD has a prevalence rate of around 5.3% in childhood
 
and 2.5-2.9% in adulthood (11,12,13). 
While the diagnosis of ADHD is based on inattentive and hyperactive-impulsive symptoms, affected 
individuals often also experience other adverse conditions. Individuals with ADHD are for example 
more likely than the general population to present with higher body mass index (BMI) (14,15), 
neurotic (16) and risk-taking (17-19) behaviour, lower IQ scores, and conditions such as bipolar 
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disorder (BD), depression, anxiety  (20-24),
 
schizophrenia  (24,25) and substance abuse 
(20,21,23,26,27). 
 
Family and twin studies suggest that several of these associations between ADHD and co-occurring 
traits and disorders are moderately to substantially explained by genetic influences (24,25,28-34). 
Until recently, the genetic overlap between ADHD and associated traits and disorders had not been 
studied using genome-wide approaches, however limited recent and yet unpublished studies using 
linkage disequilibrium score regression (LDSR) report significant genetic correlations between ADHD 
and BMI (rg=0.21-0.26), educational and cognitive measures (rg=-0.25-0.54), depression (rg=0.48), BD 
(rg=0.25), schizophrenia (rg=0.22) and smoking (rg=0.38-0.48), but not neuroticism and obsessive-
compulsive disorder (1,35). No genome-wide studies have yet investigated the genetic association 
between ADHD and risk-taking, or alcohol and drug use.  
 
While associations between ADHD and co-occurring impairments are well documented, our 
knowledge of the shared aetiological influences underlying these co-occurrences is still limited in 
regards to magnitude and type of genetic variants implicated in the genetic associations. The 
advantage of using a polygenic approach to study the genetic associations between phenotypes is 
that (1) we use molecular genetic data which do not rely on assumptions of relatedness as in twin 
studies, (2) the design captures the polygenic nature of complex traits and disorders, which in turn 
(3) increases power to detect significant effects in studies compared to those considering only the 
most associated variants or candidate genes. In contrast to LDSR, the polygenic scoring method uses 
individual-level SNP, resulting in greater statistical power data and allowing for direct testing of 
interaction effects.    
 
In this study we use a powerful polygenic approach exploiting PRS derived from the recently 
published mega-GWAS on ADHD to test whether genetic variants that contribute to ADHD also 
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influence frequently co-occurring traits and disorders in a large-scale adult population sample. A 
greater understanding of why ADHD often co-occurs with other impairing conditions may in turn 
improve preventative strategies and treatment for affected individuals. We further investigate 
whether the genetic overlap between ADHD and co-occurring features varies as a function of sex. 
Although a recent study suggested a near complete overlap of common genetic variants associated 
with ADHD between males and females (36), there may be sex differences in the genetic overlap 
between ADHD and comorbid features. 
 
Methods and Materials 
Discovery sample 
We used the recently published mega-GWAS on ADHD as the discovery dataset (1). Summary results 
were downloaded from the PGC website (https://www.med.unc.edu/pgc/results-and-downloads). 
This GWAS contains data from 55,374 children and adults (20,183 ADHD cases and 35,191 controls), 
and 8,047,421 SNPs. 12 independent loci were significantly associated with ADHD, and polygenic risk 
calculated from the GWAS explained on average up to 5.5% variance in ADHD case-control status, 
when using five different sets of discovery and independent target samples. The SNP-based 
heritability was calculated as 0.22 (1).  
 
Target sample 
Participants 
We used baseline data from the UK Biobank Study (http://www.ukbiobank.ac.uk) (41).
 
A total of 
502,655 community-dwelling participants aged between 37 and 73 years were recruited between 
2006 and 2010 through the UK National Health Service patient registers (response-rate=5.47%) and 
underwent extensive cognitive and physical assessments. We analyzed data on 135,726 individuals 
(71,874 females) aged between 40 and 73 years (mean=56.79, standard deviation; SD=7.96) who 
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had available genotyping data after quality control (detailed below). UK Biobank received ethical 
approval from the Research Ethics Committee; reference 11/NW/0382. 
 
Genotyping and quality control 
A total of 152,729 blood samples were genotyped using either the UK BiLEVE array (N=49,979) or the 
UK Biobank axiom array (N=102,750). Details on genotyping, quality control and imputation 
procedures can be found on the UK Biobank website (http://www.ukbiobank.ac.uk/scientists-
3/genetic-data/) and in Sudlow et al (37).
 
We further excluded SNPs based on minor allele frequency 
(<0.01) and missingness (>0.02), and removed participants based on missingness (>0.01), Hardy-
Weinberg equilibrium (P<10
-8
), relatedness (>0.088(r~=0.25)), gender mismatch and non-Caucasian 
ancestry. See Table 1 for the sample sizes after quality control for each phenotype. The resulting 
dataset had 512,536 SNPs and 135,726 samples available for analyses. 
 
Phenotypes 
BMI 
BMI, which is constructed from weight and height (weight(kg)/height(cm)
2
), was measured during 
the initial assessment. BMI values were excluded if data on either height or weight were missing.  
 
General cognitive ability 
Participants completed a verbal-numerical reasoning test, consisting of 13 multiple-choice questions 
(6 verbal/7 numerical) answered within a 2-minute time period (Table S1).  The test has shown a 
satisfactory level of test-retest reliability (r=0.65) and a very high genetic correlation with a general 
factor of cognitive ability (rg=0.81, P=6.2x10
-18
) (38,39).   
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Internalizing traits and psychiatric disorders 
Neuroticism was measured using 12 items (Table S2) from Eysenck Personality Inventory 
Neuroticism scale–Revised
 
(40). The score of each individual corresponds to the number of neurotic 
traits present, each coded as binary variables (1=Yes, 0=No).  
 
Primary (the most resource-intensive condition) or secondary ICD-10 diagnoses, which were 
accessed through hospital records, and self-report measures, which were reports of having 
experienced a disorder during interview with nurse, were used to identify individuals who had 
experienced instances of anxiety and depressive disorders, BD and schizophrenia (see Table S3 for 
ICD-10 codes). Individuals were indexed as having experienced a psychiatric disorder if they met 
criteria either through self-report or an ICD-10 diagnoses (any ICD subtype as seen in Table S3).  
 
Substance use and risk-taking 
Alcohol intake frequency was measured by asking participants “About how often do you drink 
alcohol?” and was coded on a 5-point scale (Table S4). Primary or secondary ICD-10 diagnoses 
(accessed through hospital records) and self-report measures (reports of having experienced a 
disorder during interview with nurse) were used to identify individuals that ever had experienced 
alcohol dependency or a mental/behavioral disorder due to alcohol use (Table S3). Information on 
smoking (ICD code: Z72.0) was accessed through hospital records. Risk-taking was measured by 
asking participants “Would you describe yourself as someone who takes risks?” and was coded as a 
binary variable (1=Yes/0=No).  
 
The control group used for comparisons with the diagnostic groups consisted of individuals that did 
not have any ICD-10 or self-reported diagnosis of alcohol dependency, anxiety disorder, depressive 
disorder, BD, schizophrenia, and did not take lithium, antidepressants or antipsychotics. 
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We did not investigate participants with ADHD as only seven individuals had an ICD-10 diagnosis 
(secondary) for ADHD or were taking stimulant medication (Methylphenidate or Ritalin) in our 
genotyped sample. There were also very few participants (n<25) diagnosed with oppositional defiant 
disorder, conduct disorder or autism spectrum disorder. The low prevalence rate of ADHD and these 
other disorders in the UK Biobank is likely due to the older age of the sample (40-73 years), as they 
are most often diagnosed in childhood but were not as commonly recognised when participants 
were school-aged children. 
 
We additionally investigated eight ‘control’ phenotypes that we did not expect to be significantly 
associated with PRS ADHD, in order to confirm that any reported significant results were not due to 
inflation of type I errors. These control traits were height, age, year of initial assessment, 
menstruation during initial assessment, number of self-reported cancers, hand grip strength, place 
of birth, visual acuity and sex of baby (more details in Table S5).   
 
PRS analyses 
PRS were computed for each UK Biobank participant using the software PRSice 
(http://www.prsice.info/) (41), with the mega-GWAS summary statistics as the discovery dataset. 
PRSice computes scores by calculating the sum of trait-associated alleles, weighted by the odds ratio 
generated from a GWAS in an independent sample. An r
2
≥0.1 (250kb window) was used for 
clumping to remove SNPs in LD. Logistic and linear regression models were used to estimate 
associations between PRS and phenotypes in the UK Biobank. PRS were calculated at a large number 
of P-value thresholds for SNP inclusion (“high resolution scoring”) (41), to provide the most 
predictive PRS. P-value thresholds were between PT=0 and PT=0.5 at increments of 0.001. Results are 
presented where the most predictive PRS is identified for each phenotype. We set a conservative 
significance threshold of P<2.1x10
-4 
for the main analyses on traits of interest and ‘control’ traits, 
based on testing the most predictive PRS across 19 phenotypes (see Methods S1). 
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We controlled for population stratification by conducting analyses with imputed markers and 15 
principal components as covariates. We included birthplace, age and sex as covariates in all analyses, 
and also batch, in order to control for any genetic differences associated with the batches that 
samples were analyses in or the genotyping platforms. The R
2
 values we report are adjusted from a 
baseline model including the covariates.  Further, we ran secondary analyses where we explored the 
effect of sex by including PRS*sex interaction effects. For these analyses, we set a stringent 
significance threshold of P<4.5x10
-4
 (Methods S1). In the prediction model for height, we added BMI 
as a covariate due to the significant phenotypic association between BMI and height (r=-0.0145, 
p=1.07*10-
24
). 
 
Results 
Table 1 summarizes the number of individuals included in analyses for each target phenotype and 
presents mean values and standard deviations for the continuous phenotypes and the number of 
‘cases’ for the binary phenotypes. 
 
BMI 
PRS for ADHD significantly (P=4.5x10
-129
) predicted BMI (R
2
=0.45%, PT=0.44;Figure 1), and the 
quantile plot demonstrates the positive nature of this relationship as BMI increases with greater 
polygenic load for ADHD (Figure 2). Mean BMI was significantly higher in males (M=27.95, SD=4.31) 
than in females (M=27.14, SD=5.23). 
 
General cognitive ability 
PRS for ADHD significantly (P=4.5x10
-36
) predicted verbal-numerical reasoning scores (R
2
=0.38%, 
PT=0.42;Figure 1) and the quantile plot shows that verbal-numerical reasoning scores decreased with 
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increasing polygenic load for ADHD (Figure 2). Verbal-numerical reasoning test scores were 
significantly higher in males (M=6.22, SD=2.18) than in females (M=6.01, SD=2.05). 
 
Internalizing traits and psychiatric disorders 
PRS for ADHD significantly (P=2.2x10
-24
) predicted neuroticism (R
2
=0.09%, PT=0.14) and the quantile 
plot demonstrates that neuroticism scores increase with higher polygenic load for ADHD (Figure 2). 
Females showed significantly higher neuroticism levels (M=4.60, SD=3.26) than males (M=3.60, 
SD=3.20), but there was no significant PRS*sex interaction effect (Table 2). We further investigated 
the separate 12 neuroticism items (Figure 1). PRS for ADHD significantly and positively predicted 
mood swings (R
2
=0.002%), fed-up feelings (R
2
=0.20%), feelings of loneliness and isolation 
(R
2
=0.19%), miserableness (R
2
=0.13%), irritability (R
2
=0.09%), being tense/highly strung (R
2
=0.07%), 
guilty feelings (R
2
=0.05%) and having easily hurt feelings (R
2
=0.05%). The PRS did not predict 
suffering from nerves, often worrying after embarrassment, being a nervous person or a worrier.  
 
PRS for ADHD also significantly (P=2.2x10
-13
) predicted depressive disorder (R
2
=0.11%, PT=0.03), 
suggestively (P=2.8x10
-4
) predicted anxiety (R
2
=0.06%, PT=0.12), but not BD or schizophrenia (Figure 
1). Quantile plots (Figure 2) show that the significant associations were positive. A significantly 
higher proportion of females than males presented with anxiety (2.6% vs 1.6%), depression (8.5% vs 
5.2%) and BD (2.3% vs 1.4%), but the opposite trend was observed for schizophrenia (0.2% vs 0.3%).  
 
Substance use and risk-taking 
PRS for ADHD significantly (P<2.1x10
-4
) predicted risk-taking (R
2
=0.12%, PT=0.29), alcohol intake 
frequency (R
2
=0.09%, PT=0.23) and dependency (R
2
=0.21%, PT=0.18) and smoking (R
2
=0.33%, 
PT=0.49). Quantile plots suggest that all these relationships were positive in nature (Figure 2). A 
significantly higher proportion of males than females were ‘risk-takers’ (36.3% vs 22.3%), alcohol 
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dependent (1.2% vs 0.4%) and smokers (2.5% vs 1.8%). Females showed significantly higher alcohol 
intake frequency (M=3.14, SD=1.53) than males (M=2.60, SD=1.42).  
 
We found no significant PRS*sex interaction effects for any of the target phenotypes (Table 2).  
 
Control phenotypes 
PRS for ADHD significantly (P<2.1*10
-4
) and negatively predicted height (R
2
=0.03%, PT=0.08) and age 
(R
2
=0.03%, PT=0.18), but not any of the remaining six control phenotypes (Table 3). After controlling 
for educational achievement (detailed in Table S6), which has been found to be genetically 
associated with height (42), the significant association between PRS for ADHD and height was no 
longer significant (R
2
=0.005%, P=0.0001), however the association between PRS and age remained, 
and was significant in both males (R2=0.021%, P=3*10-5) and females (R2=0.029%, P=8*10-6). When 
we re-ran all the main analyses controlling for educational achievement and BMI, which were the 
two additional covariates in the PRS-Height model, the overall pattern of results remained the same, 
although effect sizes decreased for most traits (Table S7).   
 
Table S4 and Figures S1-11 provide more detailed information and plots for the PRS prediction 
models. 
 
Discussion 
Using polygenic risk scores derived from the recently published mega-GWAS (1), we found that 
polygenic risk for clinically diagnosed ADHD predicts higher BMI, neuroticism, risk-taking, tobacco 
and alcohol use, anxiety and depressive disorders, and lower general cognitive ability in an adult 
population sample. These are the first reports of significant genetic associations between ADHD and 
neuroticism traits, risk-taking and alcohol use based on genome-wide data. The remaining 
associations are consistent with a relatively limited literature of studies demonstrating pleiotropy of 
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the genetic variants underlying ADHD. No sex-specific effects were observed in relation to the 
association between PRS for ADHD and co-occurring features. 
 
Individuals with many risk alleles for ADHD were more likely to have higher BMI than those with few 
risk alleles. There is limited research investigating why ADHD and high BMI often co-occur, but our 
findings, together with recent findings using LDSR (1,35), suggest that they have an overlapping 
genetic basis. Further research is needed to identify genetic pathways and neurobiological 
mechanisms relating to this genetic overlap, which could prove vital for improving prevention and 
treatment interventions for individuals with ADHD who are at risk of obesity. One possibility is that 
dopaminergic pathways and pathways implicated in eating patterns (e.g. binge- and emotional-
eating), sleeping patterns and sedentary behavior explain the association between ADHD and BMI, 
which would be in line with initial evidence (42,43,44,45,46). The common mechanisms underlying 
both ADHD and BMI could either reflect biological pleiotropy, where similar mechanisms influence 
both traits, or mediated pleiotropy, where certain mechanisms influences one of the traits, which in 
turn influences the other.  
 
PRS for ADHD was significantly associated with lower cognitive ability, which is in line with past twin 
and molecular genetic studies (2,29,30,35). The association between ADHD and general cognitive 
ability is thought to be mainly driven by ADHD symptoms that influence IQ, at least in adolescence 
(47).
 
Thus, it may be possible that there are common biological mechanisms underlying both ADHD 
and IQ, but perhaps also certain biological mechanisms underlie ADHD, which in turn influences IQ, 
possibly through poor educational achievement due to difficulties concentrating in school (47,48).
 
  
 
PRS for ADHD significantly and positively predicted neuroticism, including individual items such as 
mood swings and irritability. Two recent studies failed to find any genetic correlation between ADHD 
and neuroticism using LDSR (35,49). The discrepancy in findings may be due to the previous studies 
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having smaller sample sizes or the use of LDSR rather than polygenic scoring, potentially resulting in 
insufficient statistical power to detect effects. 
 
PRS for ADHD also predicted depression, and anxiety at a suggestive level, which is in line with 
findings from twin and genome-wide studies (9,31,32,33,35). The ADHD PRS did not predict BD or 
schizophrenia, however these results should be considered with caution as previous family-based 
and genome-wide studies using other statistical methods have reported significant genetic 
associations between these disorders (34,35). The discrepancy in findings may be due to the older 
age of our sample, the use of a population cohort rather than clear case-control groups, or 
insufficient power to detect effects, in particular for schizophrenia (288 cases) based on power 
calculations using Avengeme R package (power for analyses: BD=0.99, schizophrenia=0.22). Further 
polygenic studies are needed to investigate the association of ADHD with BD and schizophrenia 
across different study populations in order to clarify the true aetiological relationship between the 
disorders.  
 
Individuals with many risk alleles for ADHD were more likely to display alcohol dependency, higher 
alcohol intake frequency, and be smokers and risk-takers compared to those with few risk alleles. 
Previous genome-wide studies reported significant genetic associations between ADHD and smoking 
(35,50,51), but not between ADHD and alcohol use (52), and no studies to our knowledge have 
investigated the genetic association between ADHD and risk-taking. The shared genetic risk between 
ADHD and these risk-taking and health-related outcomes may be explained by common 
neurobiological mechanisms involved in self-regulation and inhibitory control. Further research 
targeting relevant genes and pathways is needed to test such hypotheses.   
 
Overall, our findings lend support for the continuous nature of ADHD across the entire population. 
We find that common risk alleles that contribute to clinically diagnosed ADHD also influence 
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common traits and disorders in the general population, across ages, which suggests that ADHD 
symptoms represent continuous traits and that similar genetic influences may be present in younger 
and older individuals. This fits well with the current understanding of ADHD based on evidence from 
behavioral, family-based and genetic studies (53,54,55).  
 
In order to investigate if our significant results could be the result of type I errors, we examined if 
PRS for ADHD significantly predicted several ‘control’ phenotypes which were not expected to be 
associated with polygenic risk for ADHD. Out of the eight ‘control’ traits, only age was significantly 
predicted by ADHD PRS. It is possible that this association is due to some real effect, such as genetic 
influences on ADHD being stronger during certain developmental periods, for example in childhood 
when the prevalence of ADHD is the highest. Twin studies suggest that the heritability of childhood 
ADHD is stronger than in adult ADHD, but this may also be due to rater effects (56). Hypothetically, 
this would then have been captured in the discovery GWAS where genetic effect sizes in children 
would be larger than in adults, and in turn lead to PRS associations with younger age in the UK 
Biobank. However, we cannot rule out the possibility that the ‘age’ result reflects a false positive or 
is due to the overlap between UK Biobank participants and those of the PGC-iPsych ADHD GWAS, 
which may cause slight inflation in results. It is reassuring, however, that seven of eight control traits 
showed non-significant results and that the relative strength of the significant results are in line with 
other preliminary genetic findings.  
 
An advantage of using a large dataset and the PRS approach is that we could directly investigate sex 
differences in the relationship between PRS and the target phenotypes. A recent study, based on the 
ADHD mega-GWAS data, found a very strong genetic correlation for ADHD across sex and no 
difference in polygenic load across sex (36), and we extend these findings to show that the polygenic 
influences underlying the relationship between ADHD and co-occurring features are similar across 
men and women.  
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Limitations and future directions 
One should interpret our findings in light of the study limitations. Our study participants were aged 
between 40 and 73 years, had a lower prevalence of mental health disorders and were recruited 
within the UK. It would be informative to investigate the generalisability of our findings by 
replicating the analyses using participants of different age-groups and from different populations. 
Selection bias of the sample could also have influenced the associations we report (57); however, we 
controlled for several important measures, including age and birthplace, in order to minimise the 
chance for bias. Further, several of the significant genetic associations that we identified confirm 
previous statistical genetic findings (35), offering some validation of our results. PRS only explain a 
tiny fraction of the variance in the target phenotypes and obtaining a complete picture of the 
aetiological overlap between ADHD and co-occurring features will require larger sample sizes and 
inclusion of other genetic factors such as copy number and rare variants.  
 
Conclusion 
In conclusion, higher polygenic load for clinical ADHD was associated with higher BMI, neurotic and 
risk-taking behavior, anxiety and depressive disorders and substance use, and lower general 
cognitive ability in the general population. These findings suggest that the co-occurrence of several 
traits and disorders with ADHD are partly explained by the same common genetic factors. Further 
investigations are needed to determine the specific neurobiological mechanisms associated with the 
shared genetic aetiology between ADHD and co-occurring features. 
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Figure legends 
 
Figure 1: Association between polygenic risk scores for ADHD and (A) target phenotypes and (B) 
items in the Neuroticism scale 
Note: Values displayed next to each bar represent the P-value for significance for the most predictive 
models. The significance threshold was set to P<2.1x10
-4
.  
 
Figure 2: Quantiles of polygenic risk scores plotted against effects on phenotypes; (A) BMI, (B) 
Verbal-numerical reasoning, (C) Alcohol intake, (D) Risk-taking, (E) Neuroticism, (F) Tobacco use, 
(G) Depression, (H) Alcohol dependency, (I) Anxiety disorder.  
Note: A regression is performed with phenotype as outcome and each 5% quantile separately, 
whereby the effect size of each quantile is compared to the central quantile as reference, such that 
each polygenic score in the quantile in question is coded 1 and each polygenic score in the reference 
quantile is coded 0. In each regression the covariates used in the main analyses are included. OR: 
Odds ratio. 
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Table 1: Rates of diagnoses and mean (SD) scores on target phenotypes 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Verbal-numerical reasoning score: number of correctly answered multiple choice questions (0-
13). Neuroticism score: number of neurotic traits present (0-12). Alcohol intake frequency: 5=Daily 
or almost daily, 4=Three or four times a week, 3=Once or twice a week, 2=One to three times a 
month, 1=Special occasions only. BMI: Body mass index. 
 
 
 
 
 
 
 
 
 
Continuous phenotypes Mean (SD) Total n 
Verbal-numerical reasoning 6.11 (2.11) 43,637 
Neuroticism 4.11 (3.27) 110,213 
Alcohol intake frequency 2.89 (1.50) 135,586 
BMI 27.52 (4.84) 135,348 
Binary phenotypes Cases n (%)  
Anxiety disorder 2,575 (2.14%) 120,362 
Depressive disorder 8,818 (6.96%) 126,605 
Bipolar disorder 2,232 (1.86%) 120,019 
Schizophrenia 288 (0.24%) 118,075 
Alcohol dependency 988 (0.83%) 118,775 
Risk-taking 39,245 (29.00%) 135,348 
Tobacco use 2,911 (2.15%) 135,348 
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Table 2: Polygenic risk score*sex interaction and main effects of sex on target phenotypes 
 
PRSM 
Beta  
PRSF 
Beta  
P 
(interaction) 
t/z 
score 
Sex 
Beta 
P 
(sex) 
t/z 
score 
BMI 0.07 0.07 0.03 -2.23 0.10 1.55*10
-725
 35.36 
Verbal-numerical 
reasoning 
-0.05 -0.07 0.12 1.55 0.05 4.82*10
-25
 10.34 
Alcohol intake 0.03 0.04 0.11 -1.62 -0.18 <2*10
-285
 -66.46 
Risk-taking 0.15 0.14 0.26 1.13 0.81 <2*10
-285
 57.70 
Neuroticism 0.03 0.03 0.52 -0.64 -0.15 <2*10
-285
 -49.19 
Tobacco use 1.10 1.33 0.57 -0.56 1.02 5.79*10
-14
 7.51 
Depressive disorders 0.45 0.27 0.36 0.91 -1.07 2.55*10
-116
 -22.93 
Alcohol dependency 1.28 2.93 0.36 -0.92 5.45 1.79*10
-39
 13.15 
Anxiety disorders 0.37 0.57 0.37 -0.89 -1.62 1.69*10
-28
 -11.07 
Bipolar disorder 0.21 0.53 0.29 -1.06 -1.79 1.73*10
-26
 -10.65 
Schizophrenia 2.56 0.40 0.29 1.06 4.35 0.00071 3.39 
Note: Significance threshold set at P<4.5x10
-4
. PRSM/F: Prediction of polygenic risk score on target 
phenotype for males and females respectively.  
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Table 3: Prediction of polygenic risk score for ADHD on target and control phenotypes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Significance threshold set at P<2.1x10
-4
 
 P PT R
2
 (%) SNPs (n) 
BMI 4.5*10
-129
 0.440 0.448 69,995 
Verbal-numerical reasoning 4.5*10
-36
 0.418 0.379 67,558 
Alcohol intake frequency 8.08*10
-29
 0.231 0.093 44,307 
Risk taking 9.3*10
-25
 0.291 0.115 52,388 
Neuroticism 2.18*10
-24
 0.139 0.092 30,306 
Tobacco use 4.2*10
-21
 0.485 0.333 74,809 
Height 8.7*10
-20
 0.081 0.030 20,147 
Depressive disorder 2.2*10
-13
 0.033 0.112 10,158 
Age (years) 5.8*10
-9
 0.177 0.026 36,443 
Alcohol dependency 2.5*10
-6
 0.175 0.208 36,101 
Anxiety disorder 2.8*10
-4
 0.116 0.062 26,355 
Visual acuity 0.005 0.001 0.029 792 
Bipolar disorder 0.007 0.117 0.037 26,551 
Hand grip strength 0.024 0.494 0.002 75,689 
Menstruation at assessment 0.115 0.051 0.025 14,128 
Number of cancers 0.127 0.131 0.002 28,929 
Schizophrenia 0.162 0.257 0.053 47,870 
Year of assessment 0.159 0.036 0.001 10,871 
Sex of child 0.234 0.010 0.062 4,085 
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Association of Polygenic Risk for Attention-Deficit/Hyperactivity 
Disorder With Co-Occurring Traits and Disorders 
Supplementary Information 
 
Supplemental Methods. Significance thresholds 
Table S1. List of items in the Verbal-Numerical Reasoning test 
Table S2. List of items in the Eysenck Personality Inventory Neuroticism scale – 
Revised (EPIN-R) 
Table S3. List of ICD-10 codes for psychiatric diagnoses used as target phenotypes 
Table S4. List of responses for alcohol intake frequency measure 
Table S5. Detailed summary of control phenotypes 
Table S6. Detailed summary of educational achievement 
Table S7. Predictive accuracy of PRS on the target phenotypes after controlling for 
BMI and educational achievement 
Figure S1. Plot for alcohol dependency 
Figure S2. Plot for alcohol intake frequency 
Figure S3. Plot for anxiety 
Figure S4. Plot for bipolar disorder 
Figure S5. Plot for BMI 
Figure S6. Plot for depressive disorder 
Figure S7. Plot for verbal-numerical reasoning 
Figure S8. Plot for neuroticism 
Figure S9. Plot for risk-taking 
Figure S10. Plot for schizophrenia 
Figure S11. Plot for tobacco use 
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Supplemental Methods 
 
Significance thresholds  
For our primary PRS analyses, we selected a conservative significance threshold to control 
for multiple testing by applying a Bonferroni correction. Euesden et al.(1) recommend using 
a significance threshold of at least P=0.004 in order to control for the high-resolution scoring 
approach of selecting the most predictive PRS. As we tested the most predictive PRS across 
each of the 11 target phenotypes, we divided the P-value by the number of tests performed 
(P=0.004/19), which resulted in a significance threshold of P=2.1x10-4.    
For our secondary analyses, where we tested the main effects of sex and PRS*sex 
interaction effects, we selected a conservative significance threshold of P=0.01 as we did 
not have strong a priori hypotheses of the effects. We applied Bonferroni correction in order 
to control for the 22 secondary analyses we ran (P=0.01/22), which resulted in a significance 
threshold of P=4.5x10-4.     
 
1. Euesden J, Lewis CM, O’Reilly PF. PRSice: Polygenic Risk Score software. Bioinformatics. 
2015;31(9): 1466-1468. 
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Table S1: List of items in the Verbal-Numerical Reasoning test 
 
 
 
 
 
 
 
 
 
 
 
  
Question Possible answers 
Add the following numbers together: 1 2 3 4 5 – is 
the answer? 
13/14/15/16/17/Do not know/Prefer not to answer 
Which number is the largest? 642/308/987/714/253/Do not know/Prefer not to 
answer 
Bud is to flower as child is to? Grow/Develop/Improve/Adult/Old/Do not 
know/Prefer not to answer 
11 12 13 14 15 16 17 18 Divide the sixth number to 
the right of twelve by three. Is the answer? 
5/6/7/8/Do not know/Prefer not to answer 
If Truda’s mother’s brother is Tim’s sister’s father, 
what relation is Truda to Tim? 
Aunt/Sister/Niece/Cousin/No relation/Do not 
know/Prefer not to answer 
If sixty is more than half of seventy-five, multiply 
twenty-three by three. If not subtract 15 from eighty-
five. Is the answer? 
68/69/70/71/72/Do not know/Prefer not to answer 
Stop means the same as? Pause/Close/Cease/Break/Rest/Do not know/Prefer 
not to answer 
If David is twenty-one and Owen is nineteen and 
Daniel is nine years younger than David, what is 
half their combined age? 
25/26/27/28/29/Do not know/Prefer not to answer 
Age is to years as height is to? Long/Deep/Top/Metres/Tall/Do not know/Prefer not 
to answer 
150...137...125...114...104... What comes next? 96/95/94/93/92/Do not know/Prefer not to answer 
Relaxed means the opposite of? Calm/Anxious/Cool/Worried/Tense/Do not 
know/Prefer not to answer 
100...99...95...86...70...What comes next? 50/49/48/47/46/45/Do not know/Prefer not to answer 
If some flinks are plinks and some plinks are stinks 
then some flinks are definitely stinks? 
False/True/Neither true nor false/Not sure/Do not 
know/Prefer not to answer 
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Table S2: List of items in the Eysenck Personality Inventory Neuroticism scale 
– Revised (EPIN-R) 
 
Note: If individuals responded ‘Do not know’ or ‘Prefer not to answer’, they were excluded from 
analyses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Question Possible answers 
Does your mood often go up and down? Yes/No/Do not know/Prefer not to answer 
Do you ever feel ‘just miserable’ for no reason?  
Are you an irritable person?  
Are your feelings easily hurt?  
Do you often feel ‘fed-up’?  
Would you call yourself a nervous person?  
Are you a worrier?  
Would you call yourself tense or ‘highly strung’?  
Do you worry too long after an embarrassing 
experience?  
Do you suffer from ‘nerves’?  
Do you often feel lonely?  
Are you often troubled by feelings of guilt?  
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Table S3: List of ICD-10 codes for psychiatric diagnoses used as target 
phenotypes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psychiatric diagnoses ICD-10 codes 
Anxiety and stress-related disorders  
Phobic anxiety disorders F40 
Other anxiety disorders F41 
Obsessive-compulsive disorder  F42 
Reaction to severe stress, and adjustment disorders 
(includes post-traumatic stress disorder) F43 
Depressive disorders  
Depressive episode F32 
Recurrent depressive disorder F33 
Bipolar affective disorder F31 
Schizophrenia, schizotypal and delusional disorders  
Schizophrenia F20 
Schizotypal disorder F21 
Persistent delusional disorders F22 
Acute and transient psychotic disorders F23 
Induced delusional disorder F24 
Schizoaffective disorders F25 
Other nonorganic psychotic disorders F28 
Unspecified nonorganic psychosis F29 
Mental and behavioural disorders due to use of 
alcohol  
Acute intoxication F10.0 
Harmful use F10.1 
Dependence syndrome F10.2 
Withdrawal state F10.3 
Withdrawal state with delirium F10.4 
Psychotic disorder F10.5 
Amnesic syndrome F10.6 
Residual and late-onset psychotic disorder F10.7 
Other mental and behavioural disorders F10.8 
Unspecified mental and behavioural disorder F10.9 
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Table S4: List of responses for alcohol intake frequency measure 
 
Note: Answers were reverse-coded and individuals who responded ‘Do not know’ or ‘Prefer not to 
answer’, were excluded from analyses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Question Possible answers 
About how often do you drink alcohol? 1=Daily or almost daily 
2=Three or four times a week 
3=Once or twice a week 
4=One to three times a month 
5=Special occasions only 
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Table S5: Detailed summary of control phenotypes 
 
 
 
 
 
 
 
 
 
 
 
  
Phenotype Description 
Covering N 
genotyped 
participants 
Mean (SD)/ 
N Cases (%) 
Height (cm) Standing height measured in centimeters during initial assessment 135,495 168.70 (9.21) 
Age (years) 
Age when attended initial assessment, derived 
from date of birth and date of attending 
assessment centre and truncated to whole year 
135,726 56.79 (7.96) 
Year of initial 
assessment 
Year when participants came in for initial 
assessment 135,726 2008.57 (0.88) 
Number of 
self-reported 
cancers 
Number of self-reported cancers recorded using 
a touch-screen self-completed questionnaire 
followed by an interview at initial assessment 
135,146 0.09 (0.31) 
Hand grip 
strength 
Hand grip strength of left hand measured using 
a Jamar J00105 hydraulic hand dynamometer. 
This measures grip force isometrically in 
kilograms. 
135,163 29.89 (11.35) 
Visual acuity 
Visual acuity of left eye measured as the 
smallest size letters that can be reliably 
identified at a specified distance. The UK 
Biobank system is based on a traditional LogMar 
chart with data captured by Direct Entry to Vox. 
29,326 0.02 (0.21) 
Menstruating 
during initial 
assessment 
Question: “Are you menstruating today? (We are 
asking this as it may affect the urine sample that 
you have been asked to provide)”. Possible 
answers: Yes, No, Do not know, Prefer not to 
answer. 
18,829 2,781 (15%) 
Sex of baby 
Sex of baby refers to the sex of the participants’ 
child as recorded across all episodes in 
hospitals. Possible codes: 0=Not known, 
1=Male, 2=Female, 3= Indeterminate, 9= Not 
specified. 
3,645 2,818 female (77%) 
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Table S6: Detailed summary of educational achievement 
 
Note: Participants that replied ‘None of the above’ or ‘Prefer not to answer’ were excluded from 
analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Description of education variable Items 
Education was based on self-report 
of highest qualification achieved. 
1=College or University degree 
2=A levels/AS levels or equivalent 
3=O levels/GCSEs or equivalent 
4=CSEs or equivalent 
5=NVQ or HND or HNC or equivalent 
6=Other professional qualifications e.g.: nursing, teaching 
-7=None of the above 
-3=Prefer not to answer 
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Table S7: Predictive accuracy of PRS on the target phenotypes after 
controlling for BMI and educational achievement 
 
 
 
 
 
 
 
 
 
 
 
  
 P PT R2 (%) 
BMI 2.7*10-99 0.121 0.342 
Verbal-numerical reasoning 2.9*10-9 0.418 0.070 
Alcohol intake frequency 2.7*10-5 0.231 0.013 
Risk taking 1.2*10-25 0.291 0.120 
Neuroticism 3.5*10-12 0.139 0.045 
Tobacco use 1.6*10-13 0.488 0.230 
Depressive disorder 1.7*10-8 0.033 0.067 
Alcohol dependency 2.6*10-5 0.175 0.177 
Anxiety disorder 0.005 0.116 0.037 
Bipolar disorder 0.041 0.117 0.022 
Schizophrenia 0.280 0.263 0.032 
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Figure S1: Plot for alcohol dependency 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2: Plot for alcohol intake frequency 
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Figure S3: Plot for anxiety 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4: Plot for bipolar disorder 
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Figure S5: Plot for BMI 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6: Plot for depressive disorder 
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Figure S7: Plot for verbal-numerical reasoning 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S8: Plot for neuroticism 
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Figure S9: Plot for risk taking 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S10: Plot for schizophrenia 
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Figure S11: Plot for tobacco use 
Note: P-value threshold represents the P-value at the cut-off for inclusion of single-nucleotide 
polymorphisms in the polygenic risk score. Values on top of the bars represent P-values for the 
regression models.  
* p-value below significance threshold.  
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